85 related articles for article (PubMed ID: 23041830)
1. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer.
Davidsson S; Ohlson AL; Andersson SO; Fall K; Meisner A; Fiorentino M; Andrén O; Rider JR
Mod Pathol; 2013 Mar; 26(3):448-55. PubMed ID: 23041830
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases.
Katz SC; Bamboat ZM; Maker AV; Shia J; Pillarisetty VG; Yopp AC; Hedvat CV; Gonen M; Jarnagin WR; Fong Y; D'Angelica MI; DeMatteo RP
Ann Surg Oncol; 2013 Mar; 20(3):946-55. PubMed ID: 23010736
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy prediction.
Ge Q; Zhao Z; Li X; Yang F; Zhang M; Hao Z; Liang C; Meng J
Clin Transl Med; 2024 Jan; 14(1):e1552. PubMed ID: 38239097
[No Abstract] [Full Text] [Related]
4. Attaining precision therapy in prostate cancer: A tall order.
Efstathiou E
Eur J Cancer; 2017 Aug; 81():226-227. PubMed ID: 28629596
[No Abstract] [Full Text] [Related]
5. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome.
Logothetis CJ; Hahn AW
Eur Urol; 2024 Jan; 85(1):3-7. PubMed ID: 37210287
[TBL] [Abstract][Full Text] [Related]
6. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer.
Ness N; Andersen S; Valkov A; Nordby Y; Donnem T; Al-Saad S; Busund LT; Bremnes RM; Richardsen E
Prostate; 2014 Oct; 74(14):1452-61. PubMed ID: 25111810
[TBL] [Abstract][Full Text] [Related]
7. FOXP3
Davidsson S; Andren O; Ohlson AL; Carlsson J; Andersson SO; Giunchi F; Rider JR; Fiorentino M
Prostate; 2018 Jan; 78(1):40-47. PubMed ID: 29105795
[TBL] [Abstract][Full Text] [Related]
8. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
Pasero C; Gravis G; Guerin M; Granjeaud S; Thomassin-Piana J; Rocchi P; Paciencia-Gros M; Poizat F; Bentobji M; Azario-Cheillan F; Walz J; Salem N; Brunelle S; Moretta A; Olive D
Cancer Res; 2016 Apr; 76(8):2153-65. PubMed ID: 27197252
[TBL] [Abstract][Full Text] [Related]
9. A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II.
Bhavsar NA; Bream JH; Meeker AK; Drake CG; Peskoe SB; Dabitao D; De Marzo AM; Isaacs WB; Platz EA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2561-7. PubMed ID: 25150281
[TBL] [Abstract][Full Text] [Related]
10. Tumor infiltrating B-cells are increased in prostate cancer tissue.
Woo JR; Liss MA; Muldong MT; Palazzi K; Strasner A; Ammirante M; Varki N; Shabaik A; Howell S; Kane CJ; Karin M; Jamieson CA
J Transl Med; 2014 Jan; 12():30. PubMed ID: 24475900
[TBL] [Abstract][Full Text] [Related]
11. From bench to bedside: immunotherapy for prostate cancer.
Tse BW; Jovanovic L; Nelson CC; de Souza P; Power CA; Russell PJ
Biomed Res Int; 2014; 2014():981434. PubMed ID: 25276838
[TBL] [Abstract][Full Text] [Related]
12. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Gulley JL; Madan RA; Tsang KY; Jochems C; Marté JL; Farsaci B; Tucker JA; Hodge JW; Liewehr DJ; Steinberg SM; Heery CR; Schlom J
Cancer Immunol Res; 2014 Feb; 2(2):133-41. PubMed ID: 24778277
[TBL] [Abstract][Full Text] [Related]
13. Dendritic and lymphocytic cell infiltration in prostate carcinoma.
Liu Y; Sæter T; Vlatkovic L; Servoll E; Waaler G; Axcrona U; Giercksky KE; Nesland JM; Suo ZH; Axcrona K
Histol Histopathol; 2013 Dec; 28(12):1621-8. PubMed ID: 23729368
[TBL] [Abstract][Full Text] [Related]
14. CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.
Leclerc BG; Charlebois R; Chouinard G; Allard B; Pommey S; Saad F; Stagg J
Clin Cancer Res; 2016 Jan; 22(1):158-66. PubMed ID: 26253870
[TBL] [Abstract][Full Text] [Related]
15. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer.
Flammiger A; Weisbach L; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
Eur J Cancer; 2013 Apr; 49(6):1273-9. PubMed ID: 23266046
[TBL] [Abstract][Full Text] [Related]
16. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
Watanabe M; Kanao K; Suzuki S; Muramatsu H; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Zennami K; Nakamura K; Tsuzuki T; Yoshikawa K; Ueda R; Sumitomo M
Prostate; 2019 Oct; 79(14):1658-1665. PubMed ID: 31390096
[TBL] [Abstract][Full Text] [Related]
17. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Zhao SG; Lehrer J; Chang SL; Das R; Erho N; Liu Y; Sjöström M; Den RB; Freedland SJ; Klein EA; Karnes RJ; Schaeffer EM; Xu M; Speers C; Nguyen PL; Ross AE; Chan JM; Cooperberg MR; Carroll PR; Davicioni E; Fong L; Spratt DE; Feng FY
J Natl Cancer Inst; 2019 Mar; 111(3):301-310. PubMed ID: 30321406
[TBL] [Abstract][Full Text] [Related]
18. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
Vicier C; Ravi P; Kwak L; Werner L; Huang Y; Evan C; Loda M; Hamid AA; Sweeney CJ
Prostate; 2021 Jan; 81(1):50-57. PubMed ID: 32986884
[TBL] [Abstract][Full Text] [Related]
19. M2 macrophages and regulatory T cells in lethal prostate cancer.
Erlandsson A; Carlsson J; Lundholm M; Fält A; Andersson SO; Andrén O; Davidsson S
Prostate; 2019 Mar; 79(4):363-369. PubMed ID: 30500076
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Expression and CD8
Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
